Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting

Dual targeting of these checkpoints through a bispecific antibody with a differentiated tolerability profile could meet an important unmet clinical need.